Blackstone Minerals (ASX:BSX) Confirms High-Grade Copper-Gold Core at Mankayan
Blackstone Minerals (ASX:BSX) confirms a high-grade copper-gold core at Mankayan, reinforcing its position as a top undeveloped project globally.
Category: Industrials
Rewardle Holdings Limited (ASX:RXH) Announces March Quarterly Activities Update
Rewardle Holdings (ASX:RXH) reports positive Q3 cash flow and strategic growth initiatives, including its partnership with CloudHolter.
Ionic Rare Earths (ASX: IXR) Advances Magnet Recycling and REE Projects
Ionic Rare Earths (ASX: IXR) reports significant progress in magnet recycling and heavy rare earth projects, reducing CO₂ emissions.
Electro Optics Systems Holdings (ASX:EOS) Reports Business Turnaround and Financial Strengthening
EOS (ASX:EOS) announces significant business restructuring, portfolio divestments, and financial repayments as part of its ongoing turnaround strategy.
Aurora Labs Limited (ASX:A3D) Completes AU4 Micro Gas Turbine Development
Aurora Labs (ASX:A3D) completes development of the AU4 micro gas turbine, advancing production and defence sector engagements.
NOVONIX Limited (ASX:NVX) Finalizes Purchase of Enterprise South Land
NOVONIX Limited (ASX:NVX) finalizes a $5 million land purchase in Chattanooga, expanding production capacity and creating up to 500 jobs.
Duxton Farms (ASX:DBF) Announces Strategic Acquisitions and Asset Sales in Q3 FY2025
Duxton Farms (ASX:DBF) reports Q3 FY2025 activities, including strategic land acquisitions and significant asset sales to support growth and shareholder returns.
Linius Technologies Limited (ASX:LNU) Unveils Strategic Restructuring and Revenue Growth Plans
Linius Technologies (ASX:LNU) restructures operations and launches a new revenue pipeline aiming for breakeven by June 2026.
BrainChip Holdings Ltd (ASX:BRN) Releases Q1 2025 Activities Report
BrainChip Holdings Ltd (ASX:BRN) releases Q1 2025 report, highlighting key partnerships and a solid financial position.
Radiopharm Theranostics (ASX:RAD) Begins Phase 2b U.S. Trial for 18F-RAD101
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.